Litcius/Paper detail

Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice

Kang Chen, Wei Wei, Lei Liu, Zhu‐Jian Deng, Le Li, Xiumei Liang, Pingping Guo, Lu‐Nan Qi, Zhiming Zhang, Wen‐Feng Gong, Shan Huang, Weiping Yuan, Liang Ma, Bang‐De Xiang, Le‐Qun Li, Jian‐Hong Zhong

2021Cancer Immunology Immunotherapy39 citationsDOIOpen Access PDF

Topics & Concepts

LenvatinibMedicineInternal medicineHazard ratioHepatocellular carcinomaAdverse effectOncologyNivolumabSorafenibCancerImmunotherapyConfidence intervalHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesCancer Mechanisms and Therapy
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice | Litcius